Introduction
are disrupted or modified. These strains provide us with systematic tools and novel opportunities to address a Sympathoadrenergic signals to the heart are detected and number of fundamental questions crucial to our underprocessed by a group of membrane proteins converting standing of the contribution by the sympathoadrenergic external signals to alterations in intracellular properties. In system to cardiac physiology and pathophysiology. These recent years, our understanding of b-and a-adrenergic questions include the difference in signaling mediated by signaling has been significantly improved. It is beyond the b AR and b AR, roles of bARK1 in bAR signaling and 1 2 scope of this review to discuss the adrenergic signaling functional regulation, activities of a AR subtypes in 1 pathways and several excellent reviews are available [1-cardiac function and hypertrophic growth, contributions of 5].
heterotrimeric G-proteins (like Gq and Gi) to the developSympathetic activation serves to maintain cardiac output ment of hypertrophy and HF, and the potential of upby enhancing inotropy, relaxation and chronotropy. Under regulating b-adrenergic signaling in HF by gene therapy. conditions of heart failure (HF), the sympathetic nervous These questions, difficult or impossible to answer using system is activated chronically and enhanced cardiac conventional methodology, are being addressed using sympathetic drive frequently precedes the onset of overt gene-targeted mice in vivo. Accumulating data from clinic symptoms and is one of the fundamental abnorresearch using murine strains have significantly advanced malities in HF [6] . In the hypertrophied and failing heart, our knowledge in this area. However, because adaptational there occurs profound desensitization of b-adrenergic changes secondary to a gene overexpression or disruption receptor (AR) signaling due to decreased b AR density, have been explored little, caution is required when attribut-1 uncoupling of bAR to stimulatory G-protein (Gs), diing all phenotypes to the direct consequences of the minished adenylyl cyclase (AC) activity, increased bAR alterations of a targeted protein. kinase (bARK) activity, and elevated content and function of inhibitory G-protein (Gi) [1, 4, 7] . The pathophysiological implications of these alterations are only partially understood.
2. Phenotypes of mice with b-or a-adrenergic Numerous mouse strains have recently been created that receptor disruption or overexpression target key components in the signaling pathways as well as these components involved in sympathetic activity (Table  Almost all subtypes of ARs have been genetically 1) . These genes are either overexpressed in the manipulated producing various strains of mice. Studies on heart, mostly under the a-myosin heavy chain promoter, or their cardiac phenotypes have yielded important insights into the physiological and pathophysiological roles of specific receptor subtypes. 1 [45] [46] [47] 2.1. Disruption of bAR system is essential for supporting circulatory function under stress such as exercise [17] . More thorough studies The role of bARs in controlling cardiac physiology has involving application of a variety of stressors or disease, been assessed by individual or combined disruption of and longitudinal follow-up of cardiac function in these genes coding for b AR, b AR or b AR [9, 13, [15] [16] [17] .
lines should provide useful information regarding the b-
Mice lacking b AR can survive to adulthood without any adrenergic mechanisms involved in regulation of cardiac 1 gross abnormalities. Baseline heart rate, blood pressure, function and onset of HF. heart weight and myocardial content of norepinephrine are similar to those seen in wild-type littermates. Increases in 2.2. Overexpression of bAR AC activity and contractile force in responses to isoproterenol were absent in b AR deficient mice whilst the 2.2.1. b AR 1 1 response to forskolin remained intact [9] . These results Mouse strains overexpressing wild-type b AR were 1 suggest that b AR is the main subtype of bARs mediating reported with a 5-15-fold increase in receptor density [8] . 1 responses to catecholamine stimulation in vivo while the These mice at very young age displayed higher levels of contribution of b AR is minor, a finding supported by the baseline heart rate and LV contractility, as well as en-2 unaltered cardiac function at baseline and during b-agonist hanced inotropic and chronotropic responses to a b-agonist stimulation in b AR knockout mice [13] . Surprisingly, isoproterenol, confirming an enhanced b AR signaling. 2 1 despite the total absence of bAR, b / b null mice Cardiomyopathy evidenced by myocyte hypertrophy and 1 2 generated by cross-breeding had similar resting heart rate, interstitial fibrosis, was evident at 8-16 weeks of age, and blood pressure and maximal exercise capacity as wild-type LV dysfunction and immature death occur around 20 mice. However, these mice did have reduced ventricular weeks [12] . These findings were confirmed by another contractility and relaxation estimated from the lower rates group in a strain of mice with b AR increased by 20- out models support the view that under basal conditions, a in the heart exhibit markedly enhanced cyclic AMP fully functional b-adrenergic system is not essential to (cAMP) content and myocardial contractility [10, 11] . This achieve normal function for a healthy heart. However, this agonist-independent b AR activation is explained by 2 existence of the active conformer of b -AR. Whereas the b-agonist stimulation, indicating the defect of Ile164 b AR 2 2 inactive conformer is by far the predominant one, with in coupling to Gs [12] . The phenotypes of Ile164 b AR
2
.100-fold increase in b AR density, the number of active mice provide strong evidence that such b AR polymor- 2 2 receptors would be substantially higher and sufficient to phism is functionally relevant and bears pathophysiological support a full physiological stimulation [10] echocardiography from 4 to 15 months of age. Within 6 way has been implied as a key mechanism for cardiac months wild-type and b AR-overexpressing mice had hypertrophic growth [4, 5] . ventricular dilatation with reduced fractional shortening Lin et al. [18] developed a strain of mice with cardiacand systolic wall thickening [53] . By 15 months the specific overexpression of a AR. These mice with over 1A cumulative mortality was 81% in the transgenic mice, 100-fold increases in a AR density display markedly 1A mainly due to HF. Hearts from these mice displayed increased LV dP/ dt but only a minor increase in dP/ max reduced number of cardiomyocytes, widespread fibrosis dt with the dP/ dt :dP/ dt ratio increased to 1.9 from min max min and severe hypertrophy [53] . Liggett et al. [11] demon-0.9 seen in wild-type controls, suggesting a selective strated that mice overexpressing b AR at higher levels enhancement of inotropy but not relaxation. LV fractional 2 (100-and 350-fold) developed fibrotic cardiomyopathy shortening was also significantly increased in a AR 1A and early death, but mice with 60-fold b AR exhibited overexpressing mice. With dP/ dt already enhanced in 2 max higher basal ventricular function but had no obvious these mice, isoproterenol was unable to increase dP/ dt max abnormalities at 12 months of age. Thus, the consequence further. The mechanism for this potent inotropic effect by of enhanced b-adrenergic activity in the heart is dependent a AR overexpression remains unclear. In contrast to the 1A on the level of transgene overexpression. Although longview of a key role of a AR in the development of 1A term b AR overexpression at very high levels is deleterihypertrophy, these mice developed no sign of cardiac 2 ous with cardiomyopathic phenotype being similar to that hypertrophy [18] . Although atrial natriuretic factor (ANF) reported in young mice overexpressing b AR [8, 48] , mRNA increased by 7-fold, expression of other hyper-1 modest b AR overexpression enhanced basal and stimutrophy-associated genes, such as myosin light chain 2v, 2 lated myocardial contractility with no pathological conseb-myosin heavy chain, and skeletal a-actin, remain unquences.
changed [18] . Polymorphisms of b AR, such as Ile164 and Gly16, by 45-fold had no deleterious effects. However, compared trophy with a 20% increase in heart weight and several to another transgenic line overexpressing equivalent fold upregulation of hypertrophy-associated genes [20, 56] . amount of wild-type b AR, these mice had lower levels of Cardiac hypertrophy in this strain is mediated by Gq as 2 heart rate, LV dP/ dt and AC activity at baseline and during concomitant expression of a Gq inhibitory peptide in these mice inhibits the development of cardiac hypertrophy [57] .
Phenotype of strains overexpressing downstream
We observed that the active mutant a AR mice with components of adrenergic signaling pathways 1B pressure overload developed more severe hypertrophy despite the fact that a AR expression and activity were Functions of several G-proteins and effector enzymes of 1A markedly suppressed [56] . In mice with cardiac overthe adrenergic signal pathways have been intensively expression of the wild-type a AR by 26-43-fold [19] , investigated using gene-targeted mouse models.
1B
there was an 8-fold increase in ANF mRNA levels but no sign of cardiac hypertrophy. Interestingly, although bAR 3.1. AR-coupled G-proteins density remained unchanged, these mice had attenuated inotropic and chronotropic responses to isoproterenol and 3.1.1. Gsa suppressed AC activity [19, 58] . These abnormalities can Gaudin et al. [22] developed a strain showing a 5-fold be reversed by inactivation of Gi with pertussis toxin overexpression of the Gsa subunit in the heart. These mice suggesting that stimulation of a AR suppresses b-adrenwithin 12 months of age displayed a higher baseline heart 1B ergic signaling via activation of Gi [19, 59] . Another rate, enhanced cardiac function and augmented inotropic possibility is activation of the Gq / protein kinase-C (PKC) and chronotropic responses to b-agonist stimulation [62] . pathway with subsequent activation of bARK1 and dowThese observations are in keeping with a facilitated nregulation and uncoupling of b AR [5, [59] [60] [61] . Indeed, signaling via bAR coupling to Gsa. At 15 months of age, 1 three PKC isoforms (d, e and b) were elevated and mice overexpressing Gsa developed cardiac abnormalities, bARK1 was increased by 3-fold in hearts overexpressing including myocyte apoptosis, necrosis, hypertrophy, intera AR [19, 61] . Compared with nontransgenic littermates, stitial fibrosis, cardiac dilatation and dysfunction. These 1B a AR transgenic mice treated with phenylephrine for 14 mice also had blunted heart rate variability and arterial 1B days displayed more severe hypertrophy, a higher bARK1 baroreflex sensitivity and a mortality of 45% by 1.5 years activity and poor survival (20 versus 90%) [61] . Disrupof age [62] [63] [64] [65] . Long-term b-blockade with propranolol tion of a AR suppressed hypertensive or vasoconstrictive reversed all these abnormalities [65] .
1B responses to a-agonist stimulation and reduced total a AR 1 density in the heart by 74% [21] . The functional conse-3.1.2. Gi quence to the heart has not been investigated.
Among the three subtypes of Gia, Gia is the most 2 abundant in the heart. Mouse lines with either knockout of Gia and Gia or expression of inducible antisense Gia 2 3 2 2.3.3. Summary have been generated [24] [25] [26] . In mice with cardiac-specific There are several novel discoveries from the studies disruption of Gia and Gia , baseline cardiac function and 2 3 outlined above. First, whereas a AR stimulation in culresponses to isoproterenol were similar to wild-type mice 1 tured rat cardiomyocytes promotes hypertrophy, there is no [25] . It is well known that stimulation of Gi-coupled evidence that activation of a AR or a AR by cardiac muscarinic receptor (M ) attenuates the bAR signaling [1] .
overexpression mediates hypertrophic growth in vivo. This In embryonic hearts lacking Gia , inhibition of iso-2 questions the role of a AR in the development of cardiac proterenol-stimulated AC activity by a M -agonist car-development of the phenotypes seen in Ro1 mice are regulation of cell growth, matrix formation and apoptosis. unexplored.
The phenotypes observed suggest a pathological role of an enhanced TGII activity in the heart.
Gqa
The mechanisms mediating hypertrophic growth and 3.2. Adenylyl cyclase progression into failure are poorly understood. Gq is likely a key factor in these processes because activating diverse At least ten isoforms of AC have been identified. The Gq-coupled receptors, including a AR, AT and ET , isoforms AC , AC and AC are the most abundant in
initiates myocardial hypertrophy [5] . Whereas no change in the heart. Mice with cardiac-directed overexpression of phenotype was observed in mice with 2-fold expression of AC and AC by 20-fold possess very similar phenotypes
wild-type Gqa subunit, the mice with 4-8-fold increase in [31] [32] [33] . Transgenic and wild-type mice have similar heart Gqa in the heart displayed hypertrophy, enhanced expresrate, echocardiographic parameters, bAR density and sion of hypertrophy-associated genes, and exhibited a 2.6-content of Gs or Gi. Upon b-agonist stimulation, the fold increase in total PKC activity. These mice also transgenic mice showed more pronounced increases in LV developed LV dilatation and suppressed ventricular concontractility and cAMP content compared to control 21 tractility. Whereas bAR density was unchanged, isolittermates [31, 32] . Mice that overexpress Ca -activated proterenol-stimulated AC activity was reduced by 70% in AC had several fold increases in AC and PKA ac-VIII conjunction with attenuated functional response [27, 66] . tivities, heightened intrinsic ventricular contractility and Histologically, interstitial fibrosis and apoptotic myocyte were unresponsive to b-agonist stimulation [33] . Interestdeath were evident [66] . In another strain with modest ingly, unlike b AR, b AR and Gsa transgenic lines, the 1 2 expression (30-56% increase at protein level) of an active AC -overexpressing mice do not develop morphological VI mutant Gqa subunit [28] , the mice at a few weeks of age or functional abnormalities in the heart up to 20 months of developed massive cardiac chamber dilatation, hypertrophy age [31] . The lack of cardiac pathology in AC mice VI and fibrosis [28] . When exposed to aortic constriction, despite the markedly enhanced b-adrenergic signaling is Gaq-overexpressing mice displayed LV dilatation and HF unclear in the mechanism but seems to indicate some whilst nontransgenic mice exhibited concentric LV hyadverse consequences by Gs-independent signals following pertrophy with maintained ejection performance [67] .
bAR overexpression. Cardiac-specific expression of a carboxyl-terminal peptide of Gqa subunit, Gqi, abolishes Gq-mediated signaling by 3.3. bAR kinase-1 and b-arrestins inducing a dominant-negative effect and the Gqi mice with aortic constriction developed much less severe cardiac 3.3.1. bARK1 hypertrophy than controls [29] . Thus, these findings conbAR rapidly loses its responsiveness in the continued firm a key role of Gq in mediating hypertrophy, apoptosis presence of agonists; a phenomenon called desensitization. and cardiomyopathy and imply the inhibition of Gaq
The recognition of blunted b-adrenergic responsiveness to signaling as a new therapeutic strategy. In accordance, catecholamines in the failing heart has stimulated research overexpression of PKC-b results in hypertrophy, enhanced to determine the underlying molecular events [1, 4, 7] . Gexpression of hypertrophy-related genes and carprotein coupled receptor kinases (GRK) phosphorylate diomyopathy [34, 35] . activated bARs leading to homologous desensitization. bARK1 (or GRK2) is one of six members of GRKs and 3.1.4. Gh the most important member in the heart [2] . The role of Gh, also known as transglutaminase II (TGII), binds and bARK1 has been thoroughly investigated in recent years hydrolyses GTP and is believed to mediate a AR-stimuby Lefkowitz, Koch and colleagues using gene-targeted 1 lated activation of PLCd1 and phosphoinositide turnover approach [36, 37, 70, 71] . Three models have been de- [68] . However, mice with 6-37-fold increase in cardiac veloped: cardiac-restricted overexpression of bARK1, TGII activity did not show an increased PKC activity at cardiac expression of a bARK1 inhibitory peptide baseline or with a -agonist stimulation [69] . This is in (bARKct) and bARK1 knockout [36, 37] . Disruption of the 1 sharp contrast to the Gqa-overexpressing mice showing bARK1 gene is embryonically lethal and bARK1-deficient markedly increased PKC activity and phosphoinositide embryos displayed marked 'hypoplasia' with thin cardiac turnover under these conditions [27, 66] . Therefore, the chamber walls, enlarged chamber sizes and a profound data do not support a coupling of Gh to a AR and reduction in LV ejection fraction [37] , indicating the 1 activation of PKC by this pathway. Interestingly Ghnecessity of bARK1 for cardiac development. Heterooverexpressing mice developed myocardial hypertrophy, zygous mice develop normally and, at maturity, display an widespread interstitial fibrosis and exhibited suppressed LV approximately 60% reduction in bARK1 activity with function [69] . It has been suggested that TGII, via catalyzenhanced LV contractility at baseline and during b-agonist ing the formation of protein cross-links, involves in stimulation [70] . In accordance, bARK1-overexpressing mice displayed attenuated inotropic response to isoto obvious cardiac abnormalities [12] and overexpression proterenol although baseline LV contractility was similar to at very high levels results in cardiomyopathy that occurs that of wild-type littermates [36] . bARKct is a peptide much later than that in b AR overexpressing mice [11, 53] . 1 corresponding to the carboxyl-terminal of bARK1 and Such distinct phenotypes of b AR versus b AR transgenic 1 2 blocks interactions of Gbg subunit and bARK1 thereby strains imply fundamental differences in their signaling preventing the activation of bARK1 [2, 37] . bARKct mechanisms [3] . Recent studies have revealed several overexpression partially inhibited bARK1 activity and differences in cardiac signaling. Both b AR and b AR 1 2 increased LV contractility at baseline and during bAR activate AC via stimulation of Gs. Compared with b AR, 1 stimulation [37] . Whereas bARK1 overexpession lead to however, biochemical and functional responses following depressed AC activity and LV contractility, these abnorstimulation of b AR are limited both spatially and tempo-2 malities were normalized by concomitant expression of rarily [3] . b AR, but not b AR, couples to Gi and 2 1 bARKct in the bARK1-overexpressing mice [71] . Imactivation of Gi antagonizes Gs-mediated signaling [3] . provement of LV contractility under basal and bAR Gi-coupling by b AR also appears to be responsible for 2 stimulated conditions was also observed in mice with the inhibition of myocyte apoptosis. This again differs bARKct expressed acutely following pressure overload from a pro-apoptotic effect of b AR stimulation or Gsa 1 [72] . These observations confirm the cardiac depressing overexpression [63, 73] . Furthermore, the bradycardiac effect of enhanced bARK1 activity through desensitization effect mediated by Gi-coupled M is enhanced in b AR- 2 2 and downregulation of b-adrenergic signaling and raise the overexpressing mice [74] but markedly attenuated in possibility of bARK1 inhibition being a treatment strategy transgenic lines expressing Gsa or b AR in the atria 1 for improving myocardial contractility when cardiac func- [64, 75] . tion is compromised. This hypothesis remains to be tested Interestingly, mice overexpressing AC or bARKct apusing specific bARK1 inhibitors.
pear to be free of cardiac abnormalities although enhanced b-adrenergic signaling is evident [31, 36] . In addition, 3.3.2. b-Arrestins higher baseline heart rates exist in b AR, b AR and Gsa 1 2 b-Arrestins consist of a family of four proteins, involved transgenic lines [8, 10, 11, 48, 49, 53, 62, 64] but not in mice in the desensitization of G-protein-coupled receptors by overexpressing AC or bARKct [31] [32] [33] 36, 70] . As chronic binding with phosphorylated receptors [2] . b-Arrestin-1 rapid pacing leads to HF in larger species, a higher basal and b-arrestin-2 are expressed in the heart and b-arrestin-1 heart rate might contribute to cardiac abnormalities in mice is more abundant. Mice lacking b-arrestin-1 appear normal with bAR or Gsa overexpressed. Despite a similar elevaand, upon stimulation with isoproterenol, display enhanced tion in basal ventricular contractility in mice overexpresfunctional responses. This is in keeping with the removal sing b AR or bARKct, only b AR mice display an 2 2 of the bAR inhibition mediated by this protein [38] . exaggerated myocardial injury when exposed to ischemia / b-arrestin-2 disruption resulted in marked augmentation reperfusion [76] . Thus, a lifetime enhancement of b-adrenand prolongation of the analgetic effect mediated by the ergic activity is not always associated with increased risk Gi / o-coupled m-opioid receptor, indicating the lack of of cardiac abnormalities and that enhanced expression of desensitization of this receptor in the absence of b-arrestineffectors such as AC or bARKct, may bypass the deleteri-2 [39] . The cardiac phenotype in these mice merits further ous consequences due to bAR or Gs overexpression. investigation.
Presynaptic factors controlling sympathetic 4. Comparison of cardiac phenotypes of b-adrenergic nervous activity signaling targeted strains
Several strains targeting the presynaptic factors of the The transgenic lines overexpressing bARs and downsympathetic nervous system, have been generated with stream components share some similar phenotypes but also either enhanced or diminished sympathetic nervous activishow several important differences.
ty. Three transgenic lines, b AR, b AR (.100-fold) and 1 2 Gsa, are similar in their development of fibrotic car-5.1. Nerve growth factor (NGF) overexpression diomyopathy, LV dysfunction and failure [8, 10, 11, 48, [62] [63] [64] [65] , providing strong evidence for the pathological role of NGF is an effector cell-derived neurotrophin and essenchronic and uncontrolled b-adrenergic activation in the tial for the survival and growth of sympathetic neurons development of HF. However, some important differences during embryonic development and maintenance of the exist among these lines. Mice with 15-40-fold expression noradrenergic phenotype. Indicative of pronounced sympaof b AR developed severe cardiomyopathy and dysfuncthetic innervation, mice with cardiac-specific overexpres-1 tion within 2-4 months of age [8, 48] . In contrast, b AR sion of NGF have higher sympathetic nerve density, a 2 expression at equivalent levels (30-60-fold) does not lead 22-fold increase in norepinephrine content and enhanced capacity of neuronal norepinephrine uptake [40, 77, 78] . release by nerve activation was inhibited by a at higher 2A Interestingly, b AR downregulation, usually seen with and by a at lower stimulatory frequencies [47] . Further-1 2C
heightened sympathetic stimulation, was not observed and more, a AR-lacking mice display tachycardia, higher 2 b AR density was actually increased by 2.3-fold. Howplasma levels of catecholamines, reduced norepinephrine 2 ever, responses to isoproterenol as measured by increase in content and bAR density, and suppressed AC activity upon 21 membrane Ca current and AC activity, were diminished b-agonist stimulation [47, 80, 81] . Thus, excessive adrenwhereas activation of AC stimulated by Gpp(NH)p or ergic stimulation due to uncontrolled norepinephrine reforskolin remained intact [77] . This latter finding implies lease, down-regulates bAR signaling. Interestingly, duel uncoupling of bARs in NGF-overexpressing hearts. Other a / a knockout mice developed ventricular hypertrophy 2A 2B
phenotypic features include a 50% increase in heart / body with suppressed LV contractility [47] . weight ratio, myocyte hyperplasia and interstitial fibrosis [40, 78] .
5.4. Summary
Disruption of enzymes for catecholamine synthesis
Presence of neuronally-derived catecholamines is essenand metabolism tial for embryonic development but is not a necessity for adulthood survival. On the contrary, excessive sympathetic Biosynthesis of catecholamines by nerve varicosities and drive to the heart, due to genetic manipulations, leads to chromaffin cells requires hydroxylation of tyrosine by expected phenotypes, including hypertrophic growth, intertyrosine hydroxylase (TH) and b-hydroxylation of dopastitial fibrosis, myocardial dysfunction and bAR desensitimine by dopamine-b-hydroxylase (DbH). Disruption of zation. These mouse strains provide novel models for the TH or DbH genes is embryonically lethal with only studies on the changes originated from uncontrolled car-5% newborns reaching adulthood [41, 42] . Thus, catecholdiac sympathetic activation. amines are essential for embryo development and loss of functional support of the heart by catecholamines might be an important reason underlying embryonic death [42] .
6. Gene complementation Feeding pregnant females with dihydroxyphenylserine, a precursor that can be converted to norepinephrine in the An important part of research using gene-targeted mice absence of DbH, prevented the lethal phenotype and the is to select candidate genes suitable for gene therapy of adult DbH-null mice can survive in the absence of HF. One approach established recently is to overexpress a catecholamines [42, 79] . Mice lacking the neuronal norepi-'therapeutic' gene in the heart of mice with carnephrine metabolizing enzyme, monoamine oxidase, diomyopathic phenotype to generate hybrid offspring showed increased content of norepinephrine in the brain carrying duel genetic manipulations. but cardiac phenotype has not been reported [43] .
Cho et al. [79] studied cardiac function in adult DbH-6.1. Gene complementation by crossbreeding deficient mice treated with dihydroxyphenylserine. LV contractility in these mice was elevated at baseline and Genetic models of dilated cardiomyopathy and HF used during b-agonist stimulated. Although total bAR density for crossbreed studies include disruption of muscle-LIM remains unchanged, the fraction of high-affinity bAR is protein [82] , overexpression of Gqa [27] , expression of a significantly greater in DbH knockout than control hearts. dominant-negative CREB transcription factor, and mutant This is most likely due to a 50% lower bARK1 activity in a-myosin heavy chain (MHC) or calsequestrin [83] [84] [85] . this strain [79] . This phenotype provides additional eviStrains that overexpress bARKct, b AR and AC were 2 dence for the profound regulation of myocardial contracmated with HF strains to introduce therapeutic genes tility by bARK1.
( Table 2) . Rockman et al. [86] crossed MLP-deficient mice with 5.3. Disruption of presynaptic a AR either bARKct-or b AR-overexpressing lines. MLP-null 2 2 mice develop a dilated cardiomyopathy, reduction in LV Release of norepinephrine from sympathetic nerve varfractional shortening and dP/ dt , and markedly blunted max icosities can be facilitated or inhibited by a variety of responses to b-agonist stimulation. Compared to wild-type receptors localized on the presynaptic neuronal membrane.
mice, the content and activity of bARK1 in the MLP Of these receptors, activation of a AR powerfully inhibits knockout mice were doubled and AC activity was sup- 2 2 norepinephrine release. The individual role of three subpressed [82, 86] . In hybrid mice from MLP-deficient / types, a , a and a , in mediating the presynaptic bARKct-crossing, all abnormalities in cardiac function and
inhibition is not clear from pharmacological studies. b-adrenergic signaling were reversed [86] . In contrast, Recent studies with knockout mice revealed that a and 200-fold overexpression of b AR in MLP-lacking mice 2A 2 a are the presynaptic a AR subtypes that inhibit norepireduced survival and facilitated the onset of HF [86] . 2C 2 nephrine release [45] [46] [47] . In cardiac tissue, norepinephrine Using a similar approach, Dorn et al. [87] crossed mice overexpressing Gqa with that overexpressing bARKct or upregulate b-adrenergic signaling in the heart are potenb AR at three levels. In contrast to MLP-deficient model, tially beneficial. Whereas the three lines overexpressing Gqa-overexpressing strains may lay in the fact that the adenoviral gene transfection [52] , and a facilitated transibARK1 activity in Gqa mice was not elevated [87] . Two tion from compensatory hypertrophy to HF following groups have successfully rescued the phenotype in Gqasurgically-induced pressure overload in mice overexpresoverexpressing mice by crossing these mice with strains sing b AR by 200-fold [91, 92] . 2 overexpressing AC [32, 88] . A complete prevention of cardiac dysfunction in Gqa /AC mice was observed V although myocardial hypertrophy and expression of hy-7. Conclusions pertrophy-associated genes remained unaffected [32] .
The effect of bARKct expression remains controversy Gene manipulation targeting the cardiac sympathobecause of findings in another three strains with caradrenergic signaling systems, together with in vivo murine diomyopathy ( Table 2) . Expression of bARKct in physiological techniques, has lead to increased recognition calsequestrin-overexpressing mice reduced bARK1 activiregarding the role of the sympathoadrenergic signaling in ty, limited ventricular dilatation and prevented immature cardiac physiology in health and disease. Whereas studies mortality [89] . However, this intervention only leads to on mouse models have confirmed data obtained with partial improvement of ventricular function in male mice classical research approaches, such as receptor agonists expressing mutant a-MHC [90] , and shows no effect in the and antagonists, surprising and interesting phenotypes have dominant-negative CREB line (a model with normal emerged from these studies. In addition, these discoveries bARK1 activity) (Koch WJ, personal communication, have established new concepts with potential targets as 1999). Co-expression of b AR either facilitated the denovel therapeutic strategies for compromised heart. The 2 velopment of HF and reduced survival in the mutant rapid increase in the numbers of both transgenic strains a-MHC mice [90] or failed to alleviate cardiomyopathy and studies using these models calls for timely summary and dysfunction in the dominant-negative CREB mice and construction of the 'phenotype database' to integrate (Table 2) . such exploding information into our knowledge. Although relatively little is known at this time, it also must be 6.2. Summary appreciated that caution is required in exploration and interpretation of phenotypes of gene-targeted mice since Crossbreed studies have proven to be a powerful tool in cardiac overexpression or disruption of a gene might alter vivo to assess the function of genes with potential for gene expression of other related genes thereby modifying the therapy of HF. These studies reveal that interventions that genuine phenotype. This work is supported by Australian National Health 
